Data Sheet (Cat.No.T11035)

TargetMol
YOUR TARGET MOLECULES

diABZI STING agonist-1 (Tautomerism)

Chemical Properties



CAS No. : 2138498-18-5

Formula: C42H51N13O7

Molecular Weight: 849.94

Appearance: no data available

Storage: store at low temperature,keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year

Biological Description

Description	diABZI STING agonist-1 (Tautomerism) (diABZI STING agonist (Compound 3)) is a selective stimulator of interferon genes (STING) receptor agonist, with EC50s of 130, 186 nM for human and mouse, respectively.
Targets(IC50)	STING
In vitro	diABZI STING agonist-1 (Tautomerism) is a selective stimulator of interferon gene (STING) receptor agonists, with EC50 of 130 and 186 nM for humans and mice, respectively. diABZI STING agonist-1 (Tautomerism) at a concentration of 1 μM showed high selectivity for more than 350 kinases tested[1].
In vivo	diABZI STING agonist-1 (Tautomerism)(subcutaneous injection; 2.5 mg/kg) induces STING-dependent activation of type I interferon and proinflammatory cytokines in vivo. diABZI STING agonist-1 (Tautomerism) (intravenous; 3 mg/kg) exhibited systemic exposure with a half-life of 1.4 hours and reached a systemic concentration greater than half the maximum effective concentration of STING in mice (EC50) 200 ng/kg) ml). diABZI STING agonist-1 (Tautomerism) (intravenous; 1.5 mg / kg; 43 days) can significantly inhibit tumor growth and significantly improve survival rate (P <0.001). Eight out of 10 mice are tumor-free[1].

Solubility Information

Solubility	DMSO: < 1mg/ml (insoluble) ,Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.1766 mL	5.8828 mL	11.7655 mL
5 mM	0.2353 mL	1.1766 mL	2.3531 mL
10 mM	0.1177 mL	0.5883 mL	1.1766 mL
50 mM	0.0235 mL	0.1177 mL	0.2353 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Ramanjulu JM, et al. Design of amidobenzimidazole STING receptor agonists with systemic activity. Nature. 2018 Nov 7.